SEARCH

SEARCH BY CITATION

FilenameFormatSizeDescription
apt4993-sup-0001-TableS1.docWord document31KTable S1. Characteristics of excluded randomised trials regarding treatment of chronic hepatitis D [NT: no treatment, n: number of patients, IFNa: interferon-alfa, RBV: ribavirin, EOT: end of treatment, EOFUP VR: virological response at the end of follow-up, m: months, FU: follow-up, X: time until normalisation of alanine aminotransferase (ALT), NR: not reported].
apt4993-sup-0002-TableS2.docWord document28KTable S2. Characteristics of randomised trials comparing IFNa monotherapy vs. no treatment (NT) (IFNa: interferon-alfa, m: months, FU: follow-up, t.i.w: three times a week).
apt4993-sup-0003-TableS3.docWord document26KTable S3. Characteristics of randomised trials comparing high dose (HD) of IFNa vs. low dose (LD) (IFNa: interferon-alfa, m: months, FU: follow-up, t.i.w: three times a week).
apt4993-sup-0004-TableS4.docWord document28KTable S4. Characteristics of randomised trials comparing IFNa monotherapy vs. IFNa plus lamivudine (LAM) (IFNa: interferon-alfa, m: months, FU: follow-up, d: day, t.i.w: three times a week).
apt4993-sup-0005-TableS5.docWord document30KTable S5. Characteristics of randomised trials comparing PEG-IFNa monotherapy vs. other treatment options (PEG-IFNa: pegylated interferon-alfa, RIBA: ribavirin, ADV: adefovir dipivoxil, m: months, FU: follow-up, d: day, w: weekly, Co: combination treatment, Ad: adefovir monotherapy).
apt4993-sup-0006-TableS6.docWord document32KTable S6. Results in randomised trials comparing IFNa monotherapy vs. no treatment (NT) (LD: low dose, HD: high dose, EOT BR: end of treatment biochemical response, EOT VR: end of treatment virological response, EOFUP VR: end of follow-up virological response, HAI: Histological Activity Index, NNT: number needed to treat, PBA: publication bias assessment).
apt4993-sup-0007-TableS7.docWord document31KTable S7. Results in randomised trials comparing low doses (LD) of IFNa vs. high doses (HD) (EOT BR: end of treatment biochemical response, EOT VR: end of treatment virological response, EOFUP VR: end of follow-up virological response, HAI: Histological Activity Index, NNT: number needed to treat, PBA: publication bias assessment).
apt4993-sup-0008-TableS8.docWord document30KTable S8. Results in randomised trials comparing IFNa monotherapy vs. combination treatment of IFNa and lamivudine (LAM) (EOT BR: end of treatment biochemical response, EOT VR: end of treatment virological response, EOFUP VR: end of follow-up virological response, HAI: Histological Activity Index, NNT: number needed to treat, PBA: publication bias assessment).
apt4993-sup-0009-TableS9.docWord document33KTable S9. Results in randomised trials comparing PEG-IFNa monotherapy vs. other treatments (EOT BR: end of treatment biochemical response, EOT VR: end of treatment virological response, EOFUP VR: end of follow-up virological response, HAI: Histological Activity Index, Co: combination treatment, Ad: adefovir monotherapy, NNT: number needed to treat, PBA: publication bias assessment).
apt4993-sup-0010-TableS10.docWord document32KTable S10. Studies of treatment of chronic HDV infection with pegylated interferon (PEG-IFN) (RCT: randomised controlled trial, RIBA: ribavirin, SVR: sustained virological response, ADV: adefovir dipivoxil).
apt4993-sup-0011-FigS1.pngPNG image21KFigure S1. Biochemical response at the end of treatment: Forest plot of trials of IFNa monotherapy vs. no intervention. Data were expressed as OR (95% CI) in a log scale.
apt4993-sup-0012-FigS2.pngPNG image41KFigure S2. Biochemical response at the end of treatment: Forest plot of trials of high doses of IFNa vs. low doses. Data were expressed as OR (95% CI) in a log scale. IFN HD: IFN high dose, IFN LD: IFN low dose.
apt4993-sup-0013-FigS3.pngPNG image21KFigure S3. Biochemical response at the end of treatment: Forest plot of trials of PEG-IFNa vs. other medications. Data were expressed as OR (95% CI) in a log scale.
apt4993-sup-0014-FigS4.pngPNG image2KFigure S4. Virological response at the end of follow-up: Forest plot of trials of IFNa monotherapy vs. no intervention. Data were expressed as OR (95% CI) in a log scale.
apt4993-sup-0015-FigS5.pngPNG image2KFigure S5. Histological improvement at the end of treatment: Forest plot of trials of IFNa monotherapy vs. no intervention. Data were expressed as OR (95% CI) in a log scale.
apt4993-sup-0016-FigS6.pngPNG image2KFigure S6. Histological improvement at the end of treatment: Forest plot of trials of IFNa plus lamivudine vs. IFNa monotherapy. Data were expressed as OR (95% CI) in a log scale.
apt4993-sup-0017-FigS7.pngPNG image21KFigure S7. Improvement in histological activity at the end of treatment: Forest plot of trials of PEG-IFNa vs. other medications. Data were expressed as OR (95% CI) in a log scale.
apt4993-sup-0018-FigS8.pngPNG image21KFigure S8. Improvement in fibrosis at the end of treatment: Forest plot of trials of PEG-IFNa vs. other medications. Data were expressed as OR (95% CI) in a log scale.
apt4993-sup-0019-FigS9.pngPNG image1KFigure S9. Intrahepatic HDAg clearance: Forest plot of trials of high doses of IFNa vs. low doses. Data were expressed as OR (95% CI) in a log scale. IFN HD: IFN high dose, IFN LD: IFN low dose.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.